

ORIGINAL ARTICLE

Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis

Steven M. Rowe, M.D., M.S.P.H., Cori Daines, M.D., Felix C. Ringshausen, M.D., Eitan Kerem, M.D., John Wilson, F.R.A.C.P., Ph.D., Elizabeth Tullis, M.D., Nitin Nair, Ph.D., Christopher Simard, M.D., Linda Han, M.D., M.P.H., Edward P. Ingenuito, M.D., Charlotte McKee, M.D., Julie Lekstrom-Himes, M.D., and Jane C. Davies, M.D., M.B., Ch.B.

ABSTRACT

BACKGROUND

Cystic fibrosis is an autosomal recessive disease caused by mutations in the *CFTR* gene that lead to progressive respiratory decline. Some mutant *CFTR* proteins show residual function and respond to the *CFTR* potentiator ivacaftor in vitro, whereas ivacaftor alone does not restore activity to Phe508del mutant *CFTR*.

METHODS

We conducted a randomized, double-blind, placebo-controlled, phase 3, crossover trial to evaluate the efficacy and safety of ivacaftor alone or in combination with tezacaftor, a *CFTR* corrector, in 248 patients 12 years of age or older who had cystic fibrosis and were heterozygous for the Phe508del mutation and a *CFTR* mutation associated with residual *CFTR* function. Patients were randomly assigned to one of six sequences, each involving two 8-week intervention periods separated by an 8-week washout period. They received tezacaftor–ivacaftor, ivacaftor monotherapy, or placebo. The primary end point was the absolute change in the percentage of predicted forced expiratory volume in 1 second (FEV₁) from the baseline value to the average of the week 4 and week 8 measurements in each intervention period.

RESULTS

The number of analyzed intervention periods was 162 for tezacaftor–ivacaftor, 157 for ivacaftor alone, and 162 for placebo. The least-squares mean difference versus placebo with respect to the absolute change in the percentage of predicted FEV₁ was 6.8 percentage points for tezacaftor–ivacaftor and 4.7 percentage points for ivacaftor alone ($P < 0.001$ for both comparisons). Scores on the respiratory domain of the Cystic Fibrosis Questionnaire–Revised, a quality-of-life measure, also significantly favored the active-treatment groups. The incidence of adverse events was similar across intervention groups; most events were mild or moderate in severity, with no discontinuations of the trial regimen due to adverse events for tezacaftor–ivacaftor and few for ivacaftor alone (1% of patients) and placebo (<1%).

CONCLUSIONS

CFTR modulator therapy with tezacaftor–ivacaftor or ivacaftor alone was efficacious in patients with cystic fibrosis who were heterozygous for the Phe508del deletion and a *CFTR* residual-function mutation. (Funded by Vertex Pharmaceuticals and others; EXPAND ClinicalTrials.gov number, NCT02392234.)

From the Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham (S.M.R.); the Arizona Respiratory Center, University of Arizona, Tucson (C.D.); the Department of Respiratory Medicine, Hannover Medical School, and the German Center for Lung Research, Hannover, Germany (F.C.R.); Hadassah Hebrew University Medical Center, Jerusalem, Israel (E.K.); Alfred Health, Melbourne, VIC, Australia (J.W.); St. Michael's Hospital, Toronto (E.T.); Vertex Pharmaceuticals, Boston (N.N., C.S., L.H., E.P.I., C.M., J.L.-H.); and Imperial College and Royal Brompton and Harefield NHS Foundation Trust, London (J.C.D.). Address reprint requests to Dr. Davies at the National Heart and Lung Institute, Imperial College London, Emmanuel Kaye Bldg., Manresa Rd., London SW3 6LR, United Kingdom, or at j.c.davies@imperial.ac.uk.

Drs. Rowe and Davies contributed equally to this article.

This article was published on November 3, 2017, at NEJM.org.

N Engl J Med 2017;377:2024–35.

DOI: 10.1056/NEJMoa1709847

Copyright © 2017 Massachusetts Medical Society.

CYSTIC FIBROSIS IS A PROGRESSIVE, SYSTEMIC, life-limiting, autosomal recessive disease that is caused by reduced quantity or function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein due to mutations in the *CFTR* gene.^{1,2} Loss of chloride transport activity due to defects in CFTR results in the accumulation of inspissated mucus in the airways, loss of exocrine pancreatic function, impaired intestinal absorption, reproductive dysfunction, and elevated sweat chloride concentration.^{1,2}

More than 270 *CFTR* mutations are known to cause cystic fibrosis.³ Disease severity and the rate of disease progression vary with mutation and are determined in part by the extent of chloride transport loss associated with each. A substantial minority of *CFTR* mutations, affecting approximately 5% of the overall population with cystic fibrosis, exhibit residual CFTR ion transport due to partially retained CFTR expression and variably preserved channel gating or function.^{4–6} These “residual function” mutations cause cystic fibrosis with lung disease and a markedly reduced life expectancy, but the disease generally progresses more slowly than more common forms of cystic fibrosis.⁷ Without the use of newborn screening, patients with cystic fibrosis that is caused by these mutations often receive a diagnosis after early infancy and are more likely to have pancreatic sufficiency and sweat chloride concentrations below 90 mmol per liter, indicating partially preserved *CFTR* activity.^{4,8,9} In contrast, the common Phe508del *CFTR* mutation, which results in cellular degradation of the protein and causes severe dysfunction when homozygous, leads to early onset of cystic fibrosis and more rapid disease progression.⁷

Two complementary types of drugs have been developed with different mechanisms of action to increase CFTR-mediated anion secretion.¹⁰ CFTR potentiators, such as ivacaftor, increase the probability of CFTR channel opening at the cell surface to enhance ion transport and are efficacious in treating gating mutations.^{11–13} CFTR correctors improve the cellular processing and trafficking of normal and mutated CFTR protein to increase the amount of functional CFTR at the cell surface. Ivacaftor-responsive CFTR mutations were identified on the basis of a clinical phenotype of residual CFTR function (which indicates the presence of functional CFTR protein on the cell surface), in vitro data, and clinical case reports.^{14,15} The ad-

dition of the CFTR corrector tezacaftor was hypothesized to enhance clinical benefit in patients with these mutations by increasing overall CFTR function; this combination treatment is particularly important for restoring activity to those carrying two copies of the Phe508del *CFTR* mutation, as shown for the approved corrector–potentiator combination lumacaftor–ivacaftor, and may provide benefit to patients with other *CFTR* mutations.^{6,16–19}

Tezacaftor is an investigational CFTR corrector that, in combination with ivacaftor, has been shown to improve lung function and decrease sweat chloride concentrations in a phase 2 clinical trial involving patients who were homozygous for the Phe508del *CFTR* mutation and patients who were heterozygous for the Phe508del *CFTR* mutation and the G551D *CFTR* mutation.²⁰ We hypothesized that this combination would also be beneficial in patients with cystic fibrosis caused by the Phe508del *CFTR* mutation and a residual-function mutation.

This phase 3, randomized, double-blind, placebo-controlled crossover trial evaluated the efficacy and safety of tezacaftor–ivacaftor combination therapy and ivacaftor monotherapy in patients 12 years of age or older who had cystic fibrosis and were heterozygous for the Phe508del *CFTR* mutation and a residual-function *CFTR* mutation.

METHODS

TRIAL DESIGN

This trial was a phase 3, randomized, multicenter, double-blind, placebo-controlled, two-period, three-intervention crossover trial (VX14-661-108, also called EXPAND) involving patients 12 years of age or older who had cystic fibrosis and were heterozygous for the Phe508del *CFTR* mutation and a second allele with a *CFTR* mutation with residual function. It was conducted at 86 sites in Australia, Europe, Israel, and North America from March 27, 2015, to February 16, 2017. (The trial protocol is available with the full text of this article at NEJM.org.) The residual-function mutations, listed in Table S1 in the Supplementary Appendix (available at NEJM.org), were identified by in vitro response to ivacaftor and population-level clinical phenotype from epidemiologic data or published literature.³ This trial was designed to evaluate the efficacy and safety of tezacaftor (VX-661, Vertex Pharmaceuticals) in combination

with ivacaftor (VX-770, Vertex Pharmaceuticals) and of ivacaftor monotherapy in this patient population with the use of an incomplete block design.

Each patient received two of the following three regimens: tezacaftor–ivacaftor combination therapy (100 mg of tezacaftor once daily and 150 mg of ivacaftor every 12 hours), ivacaftor monotherapy (150 mg of ivacaftor every 12 hours), or placebo. This trial included a screening period of up to 6 weeks, two intervention periods of 8 weeks separated by a washout period of 8 weeks, and a safety follow-up visit. Patients were enrolled and stratified according to age at screening (<18 years vs. ≥18 years), the percentage of predicted forced expiratory volume in 1 second (FEV₁) at the screening visit (<70% vs. ≥70%), and type of residual-function mutation (class V noncanonical splice mutation or class II to IV residual-function [missense] mutation) (Table S1 in the Supplementary Appendix). They were then randomly assigned (in a 1:1:1:1:1:1 ratio) to one of six intervention sequences, as shown in Figure S1 in the Supplementary Appendix.

Eligible patients who completed the week 24 visit at the end of the second intervention period were offered the opportunity to enroll in an extension study (VX14-661-110; ClinicalTrials.gov number, NCT02565914). The trial protocol was approved by an independent ethics committee at each of the trial sites before trial initiation. All enrolled patients, or the parent or legal guardian (if applicable), provided written informed consent.

The trial sponsor (Vertex Pharmaceuticals) designed the protocol in collaboration with the authors. Local site investigators (listed in the Supplementary Appendix) collected the data, which were analyzed by the sponsor. All the authors had full access to the trial data after the data were unblinded and made the decision to submit the manuscript for publication. The manuscript was written with medical writing support, which was funded by the sponsor, with critical review and input from all the authors. The authors vouch for the accuracy and completeness of the data and analyses and for the adherence of the trial to the protocol. Confidentiality agreements were in place between the sponsor and all the investigators participating in this trial.

TRIAL PARTICIPANTS

Patients 12 years of age or older who were confirmed at the screening visit to be heterozygous

for the Phe508del CFTR mutation and a second allele with a residual-function CFTR mutation were eligible for inclusion if they had a percentage of predicted FEV₁ at the time of screening that was 40 to 90% of the predicted normal values, stable lung disease, and a sweat chloride concentration of at least 60 mmol per liter. If the sweat chloride concentration was less than 60 mmol per liter, documented evidence of chronic sinopulmonary disease was required (see the Methods section in the Supplementary Appendix).

Patients were excluded if they had clinically significant laboratory abnormalities at screening (hemoglobin level <10 g per deciliter or abnormal liver or renal function); acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy for pulmonary disease within 28 days before day 1 (first dose of trial regimen) of the trial; a history of solid-organ or hematologic transplantation; recent participation in an investigational drug study or use of a commercially available CFTR modulator therapy, including ivacaftor or lumacaftor–ivacaftor; or a history of any coexisting condition that might confound the results of the trial or pose an additional risk.

TRIAL ASSESSMENTS

The primary end point was the absolute change in the percentage of predicted FEV₁ from the baseline value to the average of the week 4 and week 8 measurements in each intervention period. The key secondary end point was the absolute change in the Cystic Fibrosis Questionnaire–Revised (CFQ-R) respiratory domain score from the baseline score to the average of the week 4 and week 8 scores in each intervention period. Scores range from 0 to 100, with higher scores indicating a higher patient-reported quality of life with respect to respiratory status. Safety and side-effect profiles were assessed as a secondary objective on the basis of adverse events, clinical laboratory values, electrocardiography, vital signs, pulse oximetry, and spirometry. Additional secondary end points included the relative change in the percentage of predicted FEV₁ and the absolute change in the sweat chloride concentration (a measure of CFTR function), both from the baseline value to the average of the week 4 and week 8 measurements in each intervention period. Exploratory and additional supportive end points included the rate of pulmonary exacerbations, the

absolute change in the fecal elastase-1 level from the baseline value to the average of the week 4 and week 8 measurements, the absolute change in the immunoreactive trypsinogen level from baseline to week 8, and the absolute change in the body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) from baseline to week 8.

STATISTICAL ANALYSIS

The percentage of predicted FEV₁ was calculated according to the standards of Wang et al.²¹ (for female patients 12 to 15 years of age and male patients 12 to 17 years of age) or Hankinson et al.²² (for female patients 16 years of age or older and male patients 18 years of age or older). The primary efficacy analysis, evaluation of the absolute change in the percentage of predicted FEV₁ from the baseline value to the average of the week 4 and week 8 measurements in the tezacaftor–ivacaftor and placebo groups and in the ivacaftor monotherapy and placebo groups, was based on a mixed-effects model. The fixed effects in the model were intervention, intervention period, and percentage of predicted FEV₁ at baseline, with patient as a random effect. Statistical analyses of all secondary end points were similar to that of the analysis of the primary efficacy end point (defined further in the Methods section in the Supplementary Appendix). The type I error rate for comparisons of the active treatments with placebo for the primary end point and key secondary end point was controlled by prespecifying a gatekeeping approach. All safety analyses included patients who received at least one dose of the trial regimen, and all were based on data associated with each safety period, which extended from the first dose of the trial regimen in the intervention period to the safety evaluation visit or safety follow-up visit, or to 28 days after the last dose in the intervention period for patients who did not have a safety evaluation visit or safety follow-up visit. The proposed sample size provided the trial with approximately 90% power for a significant difference to be observed between tezacaftor–ivacaftor and placebo for the primary end point. A carryover effect was not expected; therefore, the choice of a crossover design, the evaluation of efficacy by assessment of the change from trial baseline, and the proposed analysis methods were considered to be appropriate.

RESULTS

PARTICIPANTS

A total of 248 patients were enrolled and underwent randomization. One patient assigned to placebo and 1 patient assigned to ivacaftor alone in period 1 were later deemed to be ineligible and did not receive the intervention. Of the remaining 246 patients, 234 (95%) completed both intervention periods, resulting in 481 periods that could be evaluated (Fig. S2 in the Supplementary Appendix). Baseline demographic and clinical characteristics of the patients in period 1 were similar among all groups (Table 1), with an overall mean (±SD) percentage of predicted FEV₁ of 62.3±14.5%. The demographic and clinical characteristics of the patients in period 2 were similar to the characteristics of the patients in period 1 (data not shown).

CLINICAL EFFICACY

No carryover effects were seen between intervention periods 1 and 2. Treatment with tezacaftor–ivacaftor and ivacaftor alone resulted in significant benefits with respect to the primary end point, the absolute change in the percentage of predicted FEV₁, as compared with placebo. The least-squares mean difference versus placebo from the baseline value to the average of the week 4 and week 8 measurements was 6.8 percentage points (95% confidence interval [CI], 5.7 to 7.8) for tezacaftor–ivacaftor and 4.7 percentage points (95% CI, 3.7 to 5.8) for ivacaftor alone ($P<0.001$ for both comparisons) (Table 2). The difference between tezacaftor–ivacaftor and ivacaftor alone was significant in favor of tezacaftor–ivacaftor ($P<0.001$) (Table 2).

Benefits with respect to the primary end point were observed for tezacaftor–ivacaftor and ivacaftor alone as compared with placebo as early as day 15 and were maintained through week 8 of the trial period (Fig. 1). The results of the primary end point in prespecified subgroups consistently favored tezacaftor–ivacaftor and ivacaftor alone over placebo, regardless of age, sex, baseline lung function, geographic region, use of common cystic fibrosis medications, *Pseudomonas aeruginosa* colonization status, and type of residual-function mutation (Fig. 2).

Both tezacaftor–ivacaftor and ivacaftor alone had significant benefits with respect to the key secondary end point, the absolute change in the

Table 1. Baseline Demographic and Clinical Characteristics.*

Characteristic	Placebo (N = 80)	Ivacaftor (N = 81)	Tezacaftor–Ivacaftor (N = 83)	Total (N = 244)
Female sex — no. (%)	46 (58)	40 (49)	48 (58)	134 (55)
Age at screening				
Mean — yr	32.6±13.9	36.3±15.2	35.6±13.5	34.8±14.2
Age group — no. (%)				
<18 yr	11 (14)	12 (15)	11 (13)	34 (14)
≥18 yr	69 (86)	69 (85)	72 (87)	210 (86)
Geographic region — no. (%)				
North America	39 (49)	36 (44)	45 (54)	120 (49)
Europe†	41 (51)	45 (56)	38 (46)	124 (51)
Type of residual-function mutation — no. (%)				
Class V noncanonical splice	48 (60)	48 (59)	50 (60)	146 (60)
Class II to IV residual function	32 (40)	33 (41)	33 (40)	98 (40)
Percentage of predicted FEV ₁				
Mean	62.1±14.0	62.8±14.6	61.8±14.9	62.3±14.5
Subgroup — no. (%)				
<40%	6 (8)	8 (10)	8 (10)	22 (9)
≥40 to <70%	48 (60)	46 (57)	48 (58)	142 (58)
≥70 to ≤90%	25 (31)	26 (32)	25 (30)	76 (31)
>90%	1 (1)	1 (1)	2 (2)	4 (2)
Body-mass index‡	24.6±5.0	24.5±5.5	23.6±4.6	24.2±5.1
Sweat chloride — mmol/liter§	70.7±24.0	74.9±24.3	64.1±28.9	69.9±26.1
CFQ-R respiratory domain score¶	67.8±17.5	70.0±17.7	66.5±17.9	68.1±17.7
Prescribed medications — no. (%)				
Dornase alfa	54 (68)	49 (60)	47 (57)	150 (61)
Inhaled antibiotic	23 (29)	27 (33)	26 (31)	76 (31)
Azithromycin	38 (48)	31 (38)	32 (39)	101 (41)
Bronchodilator	71 (89)	68 (84)	74 (89)	213 (87)
Inhaled bronchodilator	71 (89)	67 (83)	74 (89)	212 (87)
Inhaled hypertonic saline	39 (49)	36 (44)	43 (52)	118 (48)
Inhaled glucocorticoid	45 (56)	48 (59)	50 (60)	143 (59)
Colonization with <i>Pseudomonas aeruginosa</i> within 2 yr before screening — no. (%)				
Positive	48 (60)	45 (56)	52 (63)	145 (59)
Negative	32 (40)	36 (44)	31 (37)	99 (41)
Pancreatic insufficiency — no. (%)**				
Yes	11 (14)	11 (14)	11 (13)	33 (14)
No	56 (70)	61 (75)	60 (72)	177 (73)
Missing data	13 (16)	9 (11)	12 (14)	34 (14)

* Plus-minus values are means ±SD. Baseline was defined as the most recent nonmissing measurement before the first dose of the trial regimen during the trial. Percentages may not sum to 100 because of rounding. FEV₁ denotes forced expiratory volume in 1 second.

† Israel and Australia were categorized under Europe.

‡ The body-mass index is the weight in kilograms divided by the square of the height in meters.

§ Sweat chloride measurements were captured at baseline for 79 patients in the placebo group, 80 in the ivacaftor group, and 81 in the tezacaftor–ivacaftor group (all in the first intervention period).

¶ Scores on the respiratory domain of the Cystic Fibrosis Questionnaire–Revised (CFQ-R) range from 0 to 100, with higher scores indicating a higher patient-reported quality of life with respect to respiratory status.

|| Data include medications that were started before the first dose of the trial regimen during the trial and were continued during the first intervention period.

** Pancreatic insufficiency was defined as a fecal elastase-1 level of less than 200 µg per gram.

Table 2. Primary and Secondary End Points.*

End Point	Ivacaftor (N=156) vs. Placebo (N=161)	Tezacaftor–Ivacaftor (N=161) vs. Placebo (N=161)	Tezacaftor–Ivacaftor (N=161) vs. Ivacaftor (N=156)
<i>least-squares mean difference (95% CI)</i>			
Primary end point: absolute change in percentage of predicted FEV ₁ — percentage points	4.7 (3.7 to 5.8)†	6.8 (5.7 to 7.8)†	2.1 (1.2 to 2.9)†
Key secondary end point: change in CFQ-R respiratory domain score — points	9.7 (7.2 to 12.2)†	11.1 (8.7 to 13.6)†	1.4 (–1.0 to 3.9)‡
Other secondary end points§			
Relative change in percentage of predicted FEV ₁ — %	8.1 (6.3 to 9.9)	11.4 (9.6 to 13.2)	3.3 (1.8 to 4.8)
Absolute change in sweat chloride — mmol/liter	–4.5 (–6.7 to –2.3)	–9.5 (–11.7 to –7.3)	–5.1 (–7.0 to –3.1)

* End points reflect the change from the baseline value or score to the average of the week 4 and week 8 measurements or scores in each intervention period. Numbers of patients shown are the total numbers of patients in the intervention groups in intervention periods 1 and 2.

† P<0.001 for the between-group comparison.

‡ P=0.26 for the between-group comparison.

§ The gatekeeping approach was not applied to analyses of these end points, so no statistical significance can be claimed.

CFQ-R respiratory domain score. The least-squares mean difference versus placebo from the baseline score to the average of the week 4 and week 8 scores was 11.1 points (95% CI, 8.7 to 13.6) for tezacaftor–ivacaftor and 9.7 points (95% CI, 7.2 to 12.2) for ivacaftor alone (P <0.001 for both comparisons) (Table 2). The percentage of patients who had a clinically important difference of 4 points or greater was 65% in the tezacaftor–ivacaftor group, 58% in the ivacaftor-alone group, and 33% in the placebo group.²³ The difference in the CFQ-R respiratory domain score between tezacaftor–ivacaftor and ivacaftor alone for either analysis was not significant.

Benefits were observed in both active-treatment groups versus placebo for other secondary end points (Table 2). The gatekeeping approach was not applied to these analyses, and statistical significance cannot be claimed. Results for the relative change in the percentage of predicted FEV₁ were consistent with the findings from the primary analysis. Sweat chloride concentrations were lower (denoting better CFTR function) in patients receiving tezacaftor–ivacaftor or ivacaftor alone than in those receiving placebo (least-squares mean difference vs. placebo, –9.5 mmol per liter [95% CI, –11.7 to –7.3] for tezacaftor–ivacaftor and –4.5 mmol per liter [95% CI, –6.7 to –2.3] for ivacaftor alone) (Table 2), with a mean concentration of 59.4±29.2 mmol per liter in the tezacaftor–ivacaftor group. Summary data for ab-

solute and relative changes in FEV₁ from the baseline value to the average of the week 4 and week 8 measurements (not prespecified end points and not subjected to analyses with a mixed-effects




Figure 1. Absolute Change from Baseline in the Percentage of Predicted Forced Expiratory Volume in 1 Second (FEV₁) at Each Visit, Full Analysis Data Set.

The full analysis data set was defined as data from all randomly assigned patients with eligible CFTR mutations who received at least one dose of the trial regimen. P<0.001 for the comparison between each active-treatment group and the placebo group at each time point. P<0.05 for the comparison between the tezacaftor–ivacaftor group and the ivacaftor group at each time point. The analysis was based on a mixed-effects model for repeated measures. Data are least-squares means; I bars indicate 95% confidence intervals.



Table 3. Exploratory End Points.*

End Point	Placebo (N=161)	Ivacaftor (N=156)	Tezacaftor–Ivacaftor (N=161)
Pulmonary exacerbations			
No. of events	20	9	11
Estimated event rate per yr	0.63	0.29	0.34
Rate ratio vs. placebo (95% CI)	—	0.46 (0.21 to 1.01)	0.54 (0.26 to 1.13)
Fecal elastase-1			
No. of patients with measurements	127	118	129
Absolute change from baseline value to average of wk 4 and wk 8 measurements — $\mu\text{g/g}$	-23.1 ± 85.9	-16.1 ± 80.6	-3.4 ± 68.5
Immunoreactive trypsinogen			
No. of patients with measurements	146	149	150
Absolute change from baseline to wk 8 — ng/ml	-2.1 ± 31.8	-23.2 ± 36.4	-18.1 ± 24.5

* Plus-minus values are means \pm SD. The gatekeeping approach was not applied to analyses of these end points, so no statistical significance can be claimed.

model for repeated measures) are shown in Table S2 in the Supplementary Appendix.

Benefits with both tezacaftor–ivacaftor combination therapy and ivacaftor monotherapy were seen in some exploratory and additional, prespecified end points. These included lower levels of immunoreactive trypsinogen (a marker of pancreatic function) than with placebo and a lower rate of pulmonary exacerbations that did not reach the level of statistical significance (Table 3; also see the Results section in the Supplementary Appendix). BMI was increased in both active-treatment groups and the placebo group at week 8 (mean absolute change, 0.34 for tezacaftor–ivacaftor, 0.47 for ivacaftor alone, and 0.18 for placebo); the differences versus placebo were not analyzed for statistical significance.

SAFETY

There were no deaths in the trial. The incidence of adverse events was similar in all three intervention groups. The majority of patients had adverse events that were considered either mild or moderate in severity. Four patients (2%) in the tezacaftor–ivacaftor group, eight (5%) in the ivacaftor-alone group, and nine (6%) in the placebo group had grade 3 (severe) or grade 4 (life-threatening) adverse events (Table 4). Adverse events led to discontinuation of the trial regimen for zero patients in the tezacaftor–ivacaftor group, two patients (1%) in the ivacaftor-alone group, and one

(<1%) in the placebo group (Table 4; also see the Results section in the Supplementary Appendix).

Overall, the most common adverse events were typical of the clinical manifestations of cystic fibrosis. The most common events ($\geq 10\%$ incidence with any trial regimen), according to preferred term, were cough, infective pulmonary exacerbation of cystic fibrosis, headache, and hemoptysis. In the tezacaftor–ivacaftor group, adverse events with both an incidence of at least 5% and an incidence that was at least 1 percentage point higher than in the placebo group were an increase in sputum production, nasopharyngitis, diarrhea, and headache; in the ivacaftor-alone group, events that met these criteria were an increase in the blood level of creatine kinase and hemoptysis (Table 4). Two patients had serious adverse events of an increase in the blood level of creatine kinase with ivacaftor treatment that were considered by the treating investigator to be related to the trial regimen; no other patients had serious adverse events that were considered by the treating investigator to be related to active treatment. There were no clinically meaningful adverse trends in the levels of alanine aminotransferase, aspartate aminotransferase, total bilirubin (Table S6 in the Supplementary Appendix), or alkaline phosphatase.

Adverse events that were associated with respiratory events or respiratory symptoms were less common in the tezacaftor–ivacaftor group than in the

Table 4. Overview of Adverse Events, Safety Data Set.*

Event	Placebo (N=162)	Ivacaftor (N=157)	Tezacaftor–Ivacaftor (N=162)
<i>number of patients (percent)</i>			
Any adverse event	126 (78)	114 (73)	117 (72)
Adverse event related to the trial regimen†	38 (23)	31 (20)	37 (23)
Maximum severity of adverse event			
Mild	63 (39)	55 (35)	58 (36)
Moderate	54 (33)	51 (32)	55 (34)
Severe	8 (5)	8 (5)	4 (2)
Life-threatening	1 (<1)‡	0	0
Grade 3 or 4 adverse event	9 (6)	8 (5)	4 (2)
Serious adverse event	14 (9)	10 (6)	8 (5)
Serious adverse event related to the trial regimen†	2 (1)	2 (1)	0
Adverse event leading to discontinuation of the trial regimen	1 (<1)§	2 (1)§	0
Adverse event leading to death	0	0	0
Adverse events occurring in ≥5% of patients in any group			
Infective pulmonary exacerbation of cystic fibrosis	31 (19)	20 (13)	21 (13)
Cough	30 (19)	17 (11)	23 (14)
Fatigue	16 (10)	7 (4)	12 (7)
Hemoptysis	14 (9)	17 (11)	12 (7)
Headache	13 (8)	11 (7)	19 (12)
Pyrexia	12 (7)	2 (1)	8 (5)
Dyspnea	11 (7)	3 (2)	9 (6)
Increase in sputum production	11 (7)	12 (8)	14 (9)
Diarrhea	10 (6)	5 (3)	13 (8)
Nausea	10 (6)	3 (2)	9 (6)
Oropharyngeal pain	9 (6)	7 (4)	9 (6)
Nasal congestion	9 (6)	3 (2)	6 (4)
Nasopharyngitis	5 (3)	6 (4)	13 (8)
Increase in the blood level of creatine kinase	5 (3)	8 (5)	6 (4)

* The safety data set was defined as data from all patients who received at least one dose of the trial regimen. Adverse events were coded with the use of the *Medical Dictionary for Regulatory Activities*, version 19.1. There were a total of 447 events in the placebo group, 342 in the ivacaftor group, and 422 in the tezacaftor–ivacaftor group.

† These events were considered by the investigator to be related or possibly related to the trial regimen.

‡ One patient had multiple life-threatening adverse events (mental-status changes, acute respiratory failure, pneumothorax, infective pulmonary exacerbation of cystic fibrosis, and pneumonia), each considered serious. The trial regimen was interrupted, and the patient completed the trial.

§ One patient discontinued placebo because of adverse events of fatigue, oropharyngeal pain, productive cough, and abnormal respiration. One patient discontinued ivacaftor because of adverse events of fatigue and an increase in the blood level of creatine kinase. One patient discontinued trial participation during the washout period because of an adverse event of an increase in the blood level of creatine kinase, which occurred 1 day after the last dose of ivacaftor in intervention period 1; this patient did not participate in intervention period 2.

placebo group (see the Results section in the Supplementary Appendix). No evidence of acute bronchoconstriction or FEV₁ decrease within 2 to 4 hours after administration of tezacaftor–iva-

caftor or ivacaftor alone was noted (see the Results section in the Supplementary Appendix), a finding distinct from those with lumacaftor-based regimens.

DISCUSSION

Using a crossover design, this phase 3 trial of combined CFTR corrector–potentiator treatment in patients with cystic fibrosis who were heterozygous for the Phe508del CFTR mutation and a second mutation associated with residual CFTR activity was able to evaluate two distinct concepts: the effect of the potentiator ivacaftor on residual-function CFTR protein defects and the benefit of adding the investigational CFTR corrector tezacaftor. Tezacaftor is a broad-acting CFTR corrector that facilitates the cellular processing and trafficking of normal CFTR and multiple mutant CFTR forms, including the common Phe508del form, thereby increasing the amount of CFTR protein at the cell surface and resulting in increased chloride transport. Results showed important clinical benefit with both combination tezacaftor–ivacaftor treatment and treatment with ivacaftor alone. These findings confirm the benefits of potentiator therapy in patients with residual CFTR function mutations and the added benefit conferred by corrector–potentiator combination therapy in this population.

The benefit with respect to spirometric measurements that was observed with tezacaftor–ivacaftor — and, to a lesser extent, with ivacaftor alone — was notable. Differences versus placebo were rapid in onset and were sustained at all trial visits, similar to those in other trials of effective CFTR modulators.^{12,15,17,24–26} Furthermore, differences versus placebo were consistent across all prespecified subgroup analyses.

Significant differences between the active-treatment groups and the placebo group with respect to the CFQ-R respiratory domain score were observed, indicating benefits with regard to respiratory health in patients with cystic fibrosis.²³ The mean change with active treatment exceeded the known minimally clinically important difference, which is tightly linked to the expected benefits of treatment.²⁷

Significant benefits with respect to pulmonary exacerbations and BMI were not expected in this population treated over a period of only 8 weeks and warrant further investigation in a longer, powered study. The findings related to levels of immunoreactive trypsinogen and fecal elastase-1, although exploratory, raise the possibility that CFTR modulation with tezacaftor–ivacaftor may have the potential to improve or preserve pan-

creatic function in some patients with residual function.

Overall, tezacaftor–ivacaftor treatment was safe, with no treatment discontinuations and no new risks identified. Tezacaftor–ivacaftor combination therapy was specifically not associated with respiratory adverse events or acute, transient reductions in FEV₁, as has been reported previously regarding CFTR modulator therapy with lumacaftor.^{13,17} This represents a potential advantage of tezacaftor–ivacaftor combination therapy in patients with low baseline lung function or a component of reactive airway disease.

One of the major challenges in investigating new therapies for residual-function mutations is the relative rarity of these genotypes; hence, they were treated as a single group owing to their common epidemiologic characteristics, physiological properties, and the propensity of mutant CFTR to respond to ivacaftor alone.^{3,28} The data with ivacaftor monotherapy validate previous clinical case reports in a more controlled setting.^{14,15}

Sweat chloride concentrations, a biomarker of CFTR modulation, decreased from baseline in both active-treatment groups, a finding that is consistent with the mechanism of action of CFTR modulation. The magnitude of change in sweat chloride concentration that was observed with ivacaftor in this trial was less than that in patients with gating mutations such as the G551D CFTR mutation, even though robust lung function and CFQ-R changes were observed in the present trial.^{12,14,29} One possible cause for this difference could be that the baseline sweat chloride concentration is lower in patients with residual-function mutations than in those with gating mutations. This equates to a smaller dynamic range over which improvement can occur.^{30,31} A second cause may be the inherent differential responsiveness of gating mutations and residual-function mutations to CFTR potentiation. The varied cellular defects (processing and trafficking, gating, and conductance) that are associated with residual function would be expected to show smaller relative improvements in CFTR function with ivacaftor than would gating defects, because the principal effect of a potentiator is to restore or augment channel gating.

Our findings show the safety and efficacy of tezacaftor–ivacaftor treatment in patients who had cystic fibrosis and were heterozygous for the Phe508del CFTR mutation and a second mutation

resulting in CFTR residual function; furthermore, although our findings also show the safety and efficacy of ivacaftor alone, the combination of tezacaftor and ivacaftor had greater efficacy. These results indicate that effective CFTR modulator therapy can be beneficial in this group of patients. A companion trial (VX14-661-106) that is now reported in the *Journal*³² shows that patients who were homozygous for the Phe508del CFTR mutation also benefited from tezacaftor–ivacaftor therapy. Collectively, these data underscore the benefit of tezacaftor–ivacaftor treatment in a broad population of patients with cystic fibrosis.

The views expressed in this article are those of the authors and not necessarily those of the National Health Service (NHS), the National Institute for Health Research (NIHR), or the U.K. Department of Health.

Supported by Vertex Pharmaceuticals and in part by the NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London. Infrastructural support was provided in awards by the Cystic Fibrosis Foundation Therapeutics Development Network and the National Institutes of Health (P30DK072482, R35HL135816, and U54TR001005). No author received an honorarium or other form of financial support related to the development of this manuscript.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

We thank the patients and their families, the trial coordinators, and the trial investigators for their roles in the trial; Jennifer Taylor-Cousar, M.D., J. Stuart Elborn, M.D., Anne Munck, M.D., Edward McKone, M.D., and Lisi Wang, M.D., for their contributions to leadership of the overall clinical trial program; Leah Eardley, Ph.D. (of Vertex Pharmaceuticals), for editorial coordination and support; and Edwin Thrower, Ph.D., Jeremy Kennard, Ph.D., and Dena McWain (of Ashfield Healthcare Communications, which received funding from Vertex Pharmaceuticals) for medical writing and editorial support.

REFERENCES

1. Elborn JS. Cystic fibrosis. *Lancet* 2016; 388:2519-31.
2. O'Sullivan BP, Freedman SD. Cystic fibrosis. *Lancet* 2009;373:1891-904.
3. CFTR2.org. Clinical and functional translation of CFTR. Baltimore: Johns Hopkins University (<http://www.cftr2.org/>).
4. Castellani C, Cuppens H, Macek M Jr, et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. *J Cyst Fibros* 2008;7: 179-96.
5. Clancy JP, Jain M. Personalized medicine in cystic fibrosis: dawning of a new era. *Am J Respir Crit Care Med* 2012;186: 593-7.
6. Van Goor F, Yu H, Burton B, Hoffman BJ. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. *J Cyst Fibros* 2014;13:29-36.
7. McKone EF, Emerson SS, Edwards KL, Aitken ML. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. *Lancet* 2003; 361:1671-6.
8. Comer DM, Ennis M, McDowell C, et al. Clinical phenotype of cystic fibrosis patients with the G551D mutation. *QJM* 2009; 102:793-8.
9. Rodman DM, Polis JM, Heltshe SL, et al. Late diagnosis defines a unique population of long-term survivors of cystic fibrosis. *Am J Respir Crit Care Med* 2005;171:621-6.
10. Van Goor F, Hadida S, Grootenhuys P. Pharmacological rescue of mutant CFTR function for the treatment of cystic fibrosis. In: Fermini B, Priest BT, eds. *Topics in medicinal chemistry: ion channels*. Berlin: Springer, 2008:91-120.
11. Davies JC, Cunningham S, Harris WT, et al. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. *Lancet Respir Med* 2016;4:107-15.
12. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. *N Engl J Med* 2011;365:1663-72.
13. Rowe SM, McColley SA, Rietschel E, et al. Lumacaftor/ivacaftor treatment of patients with cystic fibrosis heterozygous for F508del-CFTR. *Ann Am Thorac Soc* 2017;14:213-9.
14. Davies J, Sheridan H, Bell N, et al. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial. *Lancet Respir Med* 2013; 1:630-8.
15. Ratjen F, Hug C, Marigowda G, et al. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial. *Lancet Respir Med* 2017;5: 557-67.
16. Van Goor F, Hadida S, Grootenhuys PD, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. *Proc Natl Acad Sci U S A* 2011;108:18843-8.
17. Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. *N Engl J Med* 2015;373: 220-31.
18. Yu YC, Sohna Y, Hwang TC. On the mechanism of gating defects caused by the R117H mutation in cystic fibrosis transmembrane conductance regulator. *J Physiol* 2016;594:3227-44.
19. Pilewski J, Higgins M, Cooke J, Nick JA. EPS1.5: a phase 3 extension study evaluating the safety and efficacy of long-term ivacaftor (IVA) in patients with cystic fibrosis (CF) and phenotypic or molecular evidence of residual CFTR function. *J Cyst Fibros* 2017;16:Suppl 1: S37. abstract.
20. Donaldson S, Pilewski J, Griese M, et al. Tezacaftor/ivacaftor in patients with cystic fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR. *Am J Respir Crit Care Med* 2017 September 20 (Epub ahead of print).
21. Wang X, Dockery DW, Wypij D, Fay ME, Ferris BG Jr. Pulmonary function between 6 and 18 years of age. *Pediatr Pulmonol* 1993;15:75-88.
22. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. *Am J Respir Crit Care Med* 1999;159:179-87.
23. Quittner AL, Modi AC, Wainwright C, Otto K, Kirihaara J, Montgomery AB. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic *Pseudomonas aeruginosa* airway infection. *Chest* 2009;135:1610-8.
24. Konstan MW, McKone EF, Moss RB, et al. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. *Lancet Respir Med* 2017;5:107-18.
25. Milla CE, Ratjen F, Marigowda G, Liu F,

- Waltz D, Rosenfeld M. Lumacaftor/ivacaftor in patients aged 6-11 years with cystic fibrosis and homozygous for *F508del-CFTR*. *Am J Respir Crit Care Med* 2017;195:912-20.
26. Moss RB, Flume PA, Elborn JS, et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an *Arg117His-CFTR* mutation: a double-blind, randomised controlled trial. *Lancet Respir Med* 2015;3: 524-33.
27. Goss CH, Quittner AL. Patient-reported outcomes in cystic fibrosis. *Proc Am Thorac Soc* 2007;4:378-86.
28. Van Goor F. Nonclinical profile of the CFTR corrector VX-661. Presented at the 30th annual North American Cystic Fibrosis Conference, Orlando, FL, October 27–29, 2016. (Poster.)
29. Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the *G551D-CFTR* mutation. *N Engl J Med* 2010;363:1991-2003.
30. Courville CA, Tidwell S, Liu B, Accurso FJ, Dransfield MT, Rowe SM. Acquired defects in CFTR-dependent β -adrenergic sweat secretion in chronic obstructive pulmonary disease. *Respir Res* 2014;15:25.
31. Wilschanski M, Dupuis A, Ellis L, et al. Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. *Am J Respir Crit Care Med* 2006;174:787-94.
32. Taylor-Cousar JL, Munck A, McKone EF, et al. Tezacaftor–ivacaftor in patients with cystic fibrosis homozygous for *Phe508del*. *N Engl J Med* 2017;377:2013-23.

Copyright © 2017 Massachusetts Medical Society.